Atlas Trials

Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy

Clinical trial NCT07627464 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07627464
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Renal Cell Carcinoma (RCC)
Start date
2026-05-31
Primary completion
2028-12-31
Enrollment
144

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.